Lineage Cell Therapeutics (LCTX) EBIAT (2016 - 2025)
Lineage Cell Therapeutics (LCTX) has 16 years of EBIAT data on record, last reported at $988000.0 in Q4 2025.
- For Q4 2025, EBIAT rose 130.44% year-over-year to $988000.0; the TTM value through Dec 2025 reached -$63.4 million, down 241.55%, while the annual FY2025 figure was -$63.4 million, 241.01% down from the prior year.
- EBIAT reached $988000.0 in Q4 2025 per LCTX's latest filing, up from -$29.8 million in the prior quarter.
- Across five years, EBIAT topped out at $988000.0 in Q4 2025 and bottomed at -$30.5 million in Q2 2025.
- Average EBIAT over 5 years is -$7.6 million, with a median of -$5.8 million recorded in 2024.
- The widest YoY moves for EBIAT: up 130.44% in 2025, down 890.08% in 2025.
- A 5-year view of EBIAT shows it stood at -$7.8 million in 2021, then rose by 18.78% to -$6.4 million in 2022, then increased by 24.85% to -$4.8 million in 2023, then surged by 32.02% to -$3.2 million in 2024, then soared by 130.44% to $988000.0 in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were $988000.0 in Q4 2025, -$29.8 million in Q3 2025, and -$30.5 million in Q2 2025.